SLC2A5 and triple-negative breast carcinoma: Although not associated with PCa, COL4A2 loss has been identified to inhibit triple-negative breast cancer cell proliferation and migration72 and its mutations as risk factor for familial cerebrovascular disease73, while inactivation of SLC2A5 has been found to inhibit cell proliferation and migration in multiple cancer cell lines74.